CPAP Efficacy in Post-COVID-19 Patients With Sleep Apnea

NCT ID: NCT06052514

Last Updated: 2025-02-07

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 22 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-01-04
• Study Completion Date: 2024-12-31

Brief Summary

This is a prospective, observational study evaluating the relationship between severity of sleep apnea with severity of cognitive fog and if treatment of sleep apnea with CPAP improves cognitive fog in a cohort of post COVID patients with sleep apnea.

Detailed Description

The overarching goal of this proposal is to evaluate the extent to which OSA may be a common, treatable comorbidity in post-COVID patients suffering from cognitive fog and whether addressing the sleep apnea may help these patients in resolving this distressing symptom.

According to the World Health Organization (WHO), "post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis". It is estimated that up to 20 to 90% of post COVID patients will have at least one persisting symptom that lasts for more than 4 months. According to the WHO, the most common symptoms include, but are not limited to shortness of breath (78%), fatigue (78%), and cognitive dysfunction (74%). It has serious economic consequences as 46% of patients were working on a reduced schedule and 23% left the workforce. Though the underlying pathology is thought to be a pan-inflammatory response, the etiology can be multifactorial. OSA is one of the possible etiologies as its symptoms and underlying inflammatory pathophysiology overlaps with that of post COVID syndrome.

Obstructive sleep apnea (OSA), a pulmonary disorder in which patients have stopping breathing episodically at night, is common, occurring in up to 60% of post COVID 19 patients. Patients with preexisting OSA have a 59% and 89% chances of developing post COVID symptoms in men and women respectively. The intermittent 'stopping breathing' episodes, sleep fragmentation and intermittent hypoxia in patients with OSA triggers a persistent, chronic low-grade inflammation within the central nervous system leading to activation of microglia and astrocytes which in turn leads to synaptic loss, neuronal necrosis and apoptosis which manifests as cognitive deficits. Interestingly, post COVID syndrome presents with similar symptoms of difficulty breathing and cognitive fog, and is associated with a similar but independent, chronic inflammatory process in the central nervous system, leading to synaptic and neuronal loss and cognitive fog. When patients with pre-existing OSA have post COVID syndrome, there may be worsening of the cognitive fog because of synergistic increase in inflammatory responses. Further, treatment of sleep apnea with CPAP can improve cognitive fog as it could decrease the inflammatory response in post COVID patients with sleep apnea. Hence, it is important to understand the relationship between the severity of OSA to the severity of cognitive fog, and if CPAP treatment can decrease the cognitive fog, thereby improve quality of life in post COVID patients.

The investigator proposes to conduct a four-week longitudinal, observational pilot study in a sample of 30 patients with sleep apnea, recruited from the post COVID clinic over a period of one year. The investigator will evaluate the severity of cognitive fog at baseline and change in cognitive fog with CPAP treatment from baseline to four weeks of follow up.

Conditions

COVID-19; Sleep Apnea

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Post COVID patient diagnosed with sleep apnea with AHI > 5

Patients with post COVID syndrome diagnosed with sleep apnea starting CPAP

Continuous positive airway pressure

Intervention Type: DEVICE

Patients with moderate or severe OSA will be treated with CPAP

Interventions

Continuous positive airway pressure

Patients with moderate or severe OSA will be treated with CPAP

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patients more than 18 years of age.
• Diagnosed with COVID and continues to have persistent symptoms beyond 4 weeks.
• Diagnosed with sleep apnea based on a home sleep study

Exclusion Criteria

• Patients with Narcolepsy or other acute Primary sleep problems.
• Cognitive impairment secondary to a neurodegenerative disorders and dementia.
• Acute exacerbation of psychiatric illness including severe depression, schizophrenia or bipolar disorder in the past 30 days.
• Serious medical or neurological illness or infection requiring hospitalization or unable to function in the past 30 days.
• Any medications that were started or change in dosage of the following medication in the past 30 days including: corticosteroids, stimulants, benzodiazepines/non benzodiazepine receptor agonists, antidepressants, antipsychotics or other medications which alter cognition.
• Patients who are on any active treatment for sleep apnea including CPAP, dental device or implant for two weeks before enrolling into the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Breathe Pennsylvania

UNKNOWN

Sponsor Role: collaborator

Venkatesh Krishnamurthy

OTHER

Sponsor Role: lead

Responsible Party

Venkatesh Krishnamurthy

Associate Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Venkatesh Krishnamurthy, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Countries

United States

Other Identifiers

STUDY23070113

Identifier Type: -

Identifier Source: org_study_id